Consumers who purchased Infants’ Tylenol for personal or household use from October 3, 2014 to January 6, 2020 may be eligible to receive part of a $6.315 million settlement in a class-action lawsuit against Johnson & Johnson Consumer Inc. (JJCI).
The lawsuit claims the packaging and advertising of Infant’s Tylenol was misleading. Per the Elkis v. Johnson & Johnson website, said packaging “deceives consumers into believing Infants’ Tylenol is unique/ specially formulated for infants, when the bottle contains liquid acetaminophen of the same concentration in Children’s Tylenol and therefore causes consumers to overpay for Infants’ Tylenol.”
Infant Tylenol’s packaging states it “Reduces fever and pain while being gentle on tummies.” It also states, “Choose TYLENOL®, #1 pediatrician recommended brand of pain reliever/fever reducer.”
JJCI denies these allegations, pointing to the “safety features of Infants’ Tylenol, especially the accompanying syringe for safe dosing of very young children, means Infants’ and Children’s are different products.”
Consumers looking to file a claim need to do so by April 13, 2020. Specifics regarding what can be claimed are stated as, “Class Members may claim $2.15 for every 1 and 2 fl. oz. bottle of Infants’ Tylenol purchased. A maximum of 7 bottles or $15.05 may be claimed without proof of purchase. An unlimited number of bottles may be claimed with proof of purchase for all Infants’ Tylenol purchases.” It could take a year or more to receive part of the settlement. A claim form can be found below.
Additionally, JJCI is being asked to update the packaging to reflect that both Infants’ Tylenol and Children’s Tylenol contains the same concentration of liquid acetaminophen.
